P/E ratio for Cellectis (CLLS)
P/E ratio as of May 2024 (TTM): -1.29
According to Cellectis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.28643. At the end of 2022 the company had a P/E ratio of -0.8974.
P/E ratio history for Cellectis from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.8974 | -67.62% |
| 2021 | -2.77 | -80.03% |
| 2020 | -13.9 | 95.35% |
| 2019 | -7.10 | -16.8% |
| 2018 | -8.54 | -17.98% |
| 2017 | -10.4 | 17.95% |
| 2016 | -8.83 | -81.69% |
| 2015 | -48.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | 23.8 | -1,953.18% | 🇺🇸 USA |
 uniQure QURE | -1.12 | -12.99% | 🇳🇱 Netherlands |
 Novavax NVAX | -0.6022 | -53.19% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.